Clinical Trial Update: AI(I)DA Acarbose and the Subclinical Inflammation [Phase 3]

View source ↗

Summary

A Phase 3 trial of acarbose for type 2 diabetes mellitus evaluating subclinical inflammation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Subclinical Inflammation
• Type 2 Diabetes Mellitus

Drugs mentioned

• Acarbose (acarbose)

Snippet

Sponsor: GWT-TUD GmbH | Conditions: Type 2 Diabetes Mellitus, Subclinical Inflammation | Phase 3 | Status: COMPLETED